For Immediate Release

DIMERIX PRESENTS AT CANACCORD DRUG & DEVICE 2025 CONFERENCE

MELBOURNE, Australia, 21 October 2025: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be presenting at the Canaccord Drug & Device Conference 2025 in Noosa, QLD on 21 October 2025.

Key points that will be covered:

- Phase 3 global clinical trial in FSGS kidney disease status and recruitment update
- Commercial partnering status

A copy of the presentation is attached.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Jane Lowe
IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au

Follow us on **LinkedIn** and **X**

Authorised for lodgement by the Board of the Company

—END—

About Dimerix Limited

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix's proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform, enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company's website at www.dimerix.com and follow on X and LinkedIn.

About DMX-200

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted by the FDA in the United States.

About FSGS

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.[1] There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,[2] underscoring the urgent need for new, disease-modifying treatments.

About ACTION3 FSGS CLINICAL STUDY **FSGS Phase 3 Study**

The Phase 3 study, which is titled "Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis", or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients are then randomised to receive either DMX-200 (120 mg capsule, twice daily) or placebo.

The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval. Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report.

References

1 *Nephcure FSGS Facts (https://nephcure.org/)*

2 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*

Dimerix

ACTION3
FSGS CLINICAL STUDY

Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs

Canaccord Genuity DRUG + DEVICE CONFERENCE 2025

Investor Presentation

October 2025

Authorised for lodgement by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report.

Overview | Phase 3 Global Opportunity

Lead drug candidate
DMX-200 in a **Phase 3 clinical trial** for focal segmental glomerulosclerosis (FSGS)

FSGS indication
a **rare disease** that causes scar tissue of kidneys, which leads to irreversible kidney damage[1]

No approved treatments
available to treat FSGS:
damage can lead to **dialysis, transplant or death**[1]

Orphan drug designation
regulatory, marketing exclusivity and pricing **benefits** in key territories[2]

4
DMX-200 licensing partners across key territories[3]

~$1.4 billion
in total upfront & potential development and sales milestone payments **plus** royalties[3]

>$65 million
in total **payments received** to date[1]

QYTOVRA®
[REPAGERMANIUM]

DMX-200 (QYTOVRA® in some territories)

Dimerix

1. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 2. ASX releases: 14Dec15, 21Nov18, 07Jun21; 3. ASX release 05 October 2023, 27 May 2024, 07 January 2025 and 01 May 2025

Cycle of damage :

What is FSGS?

Focal	**= some**
Segmental	**= sections**
Glomerulo	**= of the kidney filtering units**
Sclerosis	**= are scarred**

in glomerular diseases

Existing blood pressure medication

DMX-200



1. Lewis, E. J. et al. (2001), New Engl J Medicine 345, 851–860

Dimerix

Measuring kidney damage – surrogate endpoints

1. Estimated glomerular filtration rate (eGFR)



- Kidney function can be measured using eGFR:
  - how many millilitres of blood is filtered by the kidney per minute
- eGFR slope naturally declines as we age[1]
- In FSGS patients, it is crashing

2. Proteinuria

- A healthy kidney is a good filter and allows little to no protein in the urine[2]



- When kidneys are damaged, protein can leak into the urine causing proteinuria
- Proteinuria represents an important early marker of kidney function[3]

Dimerix

1. National Kidney Foundation: Estimated Glomerular Filtration Rate (eGFR): https://www.kidney.org/atoz/content/gfr; 2.Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 3. Nephcure FSGS living with the disease (2024) at https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerular-diseases/understanding-fsgs/

ACTION3 phase 3 clinical trial

FSGS CLINICAL STUDY

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB

~286
Total number of adult patients required - anticipated H2 2025[1]

257
Patients recruited, randomised and dosed, including adults and paediatric patients[2]

59
Patients enrolled over into open label extension study[2]

Background

- Patients recruited, then screened and stabilised on background medications
- Patients randomised to receive drug or placebo
- DXB remains blinded at all times during study

Phase 3 Trial Timeline



Open Label Extension

DMX-200

★ *Potential to submit for conditional marketing approval, subject to FDA discussion [3]*

Dimerix

1. ASX release 30 Dec 2024; 2. As at 20 October 2025, including 254 adults and 3 paediatric patients; 3. Interim Phase 3 analysis data does not guarantee a statistically significant outcome at the end of the trial, ASX release 11 March 2024; 4. The potential for accelerated (or conditional) approval submissions, following the second interim analysis and any required unblinding, will be assessed based on outcomes from PARASOL analysis, recommendations of the IDMC and discussions with the appropriate regulatory authorities such as the FDA in the US; 5. Regardless of any accelerated (conditional) approval potential, ACTION3 study will complete full 2 year analysis and regulatory submission for potential traditional (full) approval; uPCR = urinary proteinuria; eGFR = estimated glomerular filtration rate (kidney function);

Blinded analysis process

PARASOL collaboration: observational data analysis of major renal registries completed[1,2]

- results of this analysis are generally consistent with the broader PARASOL analysis conducted in 2024
- potential relationship between proteinuria at 12 months and subsequent risk of kidney failure observed that may further support proteinuria as an endpoint for marketing approval

Step 1

PARASOL FSGS working group 12-month data analysis received[1]

Step 2

Seek FDA alignment on endpoints and process for traditional and potential accelerated approval[2]

Assuming FDA aligned with endpoints

Step 3

Blinded statistical powering analysis outcome and ACTION3 clinical study protocol updates[2,3]

Timing subject to acceptance of protocol update in each territory

Step 4

Final decision on submission for accelerated approval and potential unblinding[2,3]

~3 months[4]

~1 month[4]

In line with best practice, endpoints must be set prior to any potential unblinding of data, to maintain integrity of the study

Dimerix

1. ASX release 08 October 2025; 2. ASX release 28 April 2025; 3. The potential for unblinding and accelerated (or conditional) approval submissions will be assessed based agreement with the appropriate regulatory authorities such as the FDA in the US and the outcomes of the planned blinded analysis; 4. Timing subject to FDA feedback and regulatory acceptance in each territory

Rare kidney disease – a potential growth market

Biopsy

FSGS diagnosis driven by rates of biopsy - growth potential as biopsy rates increase

7 per 1,000,000

Global incidence rate of FSGS per capita per year[1]

FSGS is the most frequent primary glomerular disease that reaches end-stage renal failure in the US[2]

DMX-200

Commercial manufacturing sites established in USA[3]

Example pricing: USA retail price for IgA Nephropathy products



Example ex-US pricing for other rare kidney disease drugs:

- in the US (i.e. Filspari in IgAN)[8] : **US$9,900 p/month**
- in Europe/UK (i.e. Kinpeygo/Tarpeyo)[9] : **US$8,267 p/month**
- Other key territories, including Middle East and China, use US and/or Europe as pricing referenc[10,11]

Dimerix

1. Kitiyakara et al Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003 Mar;23(2):172-82. doi: 10.1053/snep.2003.50025. PMID: 12704577; 2. The United States Renal Data System (USRD), 2023 Annual Report, End Stage Renal Disease; 3. ASX investor presentation 09Mar20; 4. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-travere-therapeutics-kidney-disorder-drug-2023-02-17/; 5. http://www.vanrafia.com; 6. Ito, et al., 2025. https://doi.org/10.1182/blood.2024025176; 7. https://endpts.com/fda-clears-traveres-rare-kidney-disease-drug-will-come-with-rems-program; 8. https://www.calliditas.se/en/wp-content/uploads/sites/2/2018/01/fda-approval-webcast-presentation.pdf; 9. Kanavos, P et al. (2018) Pharmaceutical pricing and reimbursement in the Middle East and North Africa region; 10. J Mark Access Health Policy. 2016 Mar 15;4:10.3402/jmahp.v4.30458. doi: 10.3402/jmahp.v4.30458

Summary of licensing deals for DMX-200 to date

Dimerix has successfully partnered DMX-200 across key markets



Licensing deals collectively valued up to

~AU$1.4 billion

in total upfront and potential milestone fees plus royalties[1]

Over

AU$65 million

in total payments received

Significant potential additional global **deal value remains**, as Dimerix pursues and progresses **licensing opportunities** with potential partners outside the licensed territories

1. ASX release 01 May 2025; 2. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023; 3. Based on US dollar conversions & further terms outlined in ASX Announcement on 27 May 2024; 4. Based on Japanese ¥ Yen conversions & further terms outlined in ASX Announcement on 7 January 2025

Corporate overview

Ticker Symbol	ASX: DXB
Cash Balance (Jun25)	$68.3 million
Market Capitalisation[1]	$312 million
Share price[1]	$0.52
Total ordinary shares on issue[1]	600,184,606
Average Daily Liquidity by value for past 30 trading days[2]	$1.03 million

SHARE PRICE



SUBSTANTIAL SHAREHOLDERS[3]

Position	Holder Name	Holding	% IC
1	Mr P Meurs	87,259,311	14.5%
TOTAL (TOP 5) Shareholders		**139,752,905**	**23.3%**

1. As at 20 October 2025; 2. Past 30 trading days liquidity as at 20 October 2025; 3. Shareholder register as at 20 October 2025

Potential catalysts

CY 2025

1 Q1/Q2 2025

- ✓ DMX-200 **licensed in US** for up to ~AU$940 million[1]
- ✓ DMX-200 **licensed in Japan** for up to ~AU$107 million[2]
- ✓ Positive Type C meeting: **FDA confirmed** proteinuria-based endpoint acceptable for full marketing approval in the US[3]
- ✓ First **development milestone** received from FUSO of AU$4.1 million [4]

2 Q3/Q4 2025

- ✓ Outcome of PARASOL working group analysis received 8 October 2025[5]
- ➢ FDA feedback anticipated Q4 2025[6]
- ➢ Blinded **interim data collection** anticipated in Q4 2025[3]
  - Potential for **accelerated (or conditional) approval** submission, subject to FDA feedback and blinded analysis outcomes[3,6,7]
- ➢ **Full study recruitment** of 286 adult patients anticipated in H2 2025[7]
- ➢ Additional **pipeline** opportunity(s) identified

3 Potential upside

- ➢ Additional **licensing partners** for DMX-200: Dimerix continues to pursue potential licensing opportunities in un-licensed territories, including China
- ➢ Additional development **milestone payments** from existing licensees if milestone achieved

Dimerix

1. ASX release 01 May 2025; 2. ASX release 07 January 2025 3. FDA Meeting Outcomes, ASX release 28 April 2025; 4. ASX release 30 June 2025; 5. ASX release 08 October 2025; 6. ASX Presentation 07 August 2025; 7. ASX release 30 December 2024